In the CCLG group there was a clear trend with age; the proportions receiving single modality treatment were 94% (age 0–9 years), 75% (age 10–14 years), 68% (age 15–19 years) and 59% (age 20–35 years), indicating that older patients tended to be given both therapies.
← all excerpts
Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92.
1
—
—